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Abstract 
Background: Myeloproliferative neoplasms (MPNs) including the classic entities; polycythemia vera (PV), essential 
thrombocythemia (ET) and primary myelofibrosis are rare diseases with unknown aetiology. The MOSAICC study, is an 
exploratory case–control study in which information was collected through telephone questionnaires and medical 
records.
Methods: As part of the study, 106 patients with MPN were asked about their perceived diagnosis and replies cor-
related with their haematologist’s diagnosis. For the first time, a patient perspective on their MPN diagnosis and clas-
sification was obtained. Logistic regression analyses were utilised to evaluate the role of variables in whether or not a 
patient reported their diagnosis during interview with co-adjustment for these variables. Chi square tests were used 
to investigate the association between MPN subtype and patient reported categorisation of MPN.
Results: Overall, 77.4 % of patients reported a diagnosis of MPN. Of those, 39.6 % recognised MPN as a ‘blood condi-
tion’, 23.6 % recognised MPN as a ‘cancer’ and 13.2 % acknowledged MPN as an ‘other medical condition’. There was 
minimal overlap between the categories. Patients with PV were more likely than those with ET to report their disease 
as a ‘blood condition’. ET patients were significantly more likely than PV patients not to report their condition at all. 
Patients from a single centre were more likely to report their diagnosis as MPN while age, educational status, and 
WHO re-classification had no effect.
Conclusions: The discrepancy between concepts of MPN in patients could result from differing patient interest 
in their condition, varying information conveyed by treating hematologists, concealment due to denial or financial 
concerns. Explanations for the differences in patient perception of the nature of their disease, requires further, larger 
scale investigation.
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Background
Myeloproliferative neoplasms (MPNs) including poly-
cythemia vera (PV), essential thrombocythemia (ET) 
and primary myelofibrosis (PMF) are rare, heterogene-
ous diseases with a reported pooled incidence rate of 
0.84, 1.03 and 0.47 for PV, ET and PMF, respectively [1]. 
MPNs are characterised by an overproduction of mature 
and immature cells in one or more cell types within the 
myeloid lineage. Overall survival of PV and ET is respect-
able with median survival of 10–16 years for PV [2] and 
10–22  years for ET [2, 3]. PMF confers much poorer 
median survival of 4–5  years [4]. These figures reflect 
the high prevalence of PV and ET compared to PMF in 
the general population [1]. In 2008, the World Health 
Organisation (WHO) officially changed the classifica-
tion of these conditions to neoplastic due to their dem-
onstrated acquired clonality [5]. MPNs possess great 
Open Access
Experimental Hematology & 
Oncology
*Correspondence:  m.mcmullin@qub.ac.uk 
†Mary Frances McMullin and Glen James are joint first authors
6 Department of Haematology, Belfast City Hospital, Queen’s University 
Belfast, C Floor, Lisburn Road, Belfast BT9 7AB, Northern Ireland, UK
Full list of author information is available at the end of the article
Page 2 of 5McMullin et al. Exp Hematol Oncol  (2016) 5:14 
genetic complexity which contributes to disease patho-
genesis and outcome [6]. Major advances in understand-
ing the genetic complexity of these diseases first came 
in 2005 when the Janus Kinase 2 (JAK2) V617F acquired 
mutation was discovered, altering diagnostic classifica-
tion and leading to new treatments for MPNs [7]. Fur-
ther acquired abnormalities in MPN were the discovery 
of mutations in the thrombopoietin receptor (MPL) [8] in 
2006 and calreticulin (CALR) in 2013, further revolution-
ising our understanding, diagnostic classification, treat-
ment and prognosis of MPNs [9, 10].
The aetiology of these diseases remains elusive with lim-
ited information available on potential risk factors. A sys-
tematic review conducted by Anderson et  al. identified 
some medical, environmental and lifestyle risk factors to 
be associated with MPNs [11]. Registration and collection 
of MPN data has been limited. Cancer registries, for exam-
ple in the UK and USA with adequate healthcare resources, 
did not begin a comprehensive collection of MPN data 
until very recently due to the change in classification of 
these diseases to cancer [12–14]. Additionally, in countries 
with limited healthcare resources, diagnostic accuracy and 
registration of MPNs, particularly in the JAK2 era, where 
genetic testing is not feasible, may contribute to misclassifi-
cation and under-reporting of MPNs [15–17].
The unknown aetiology of MPNs justified the need for 
conducting a pilot exploratory case–control study, to 
firstly ascertain optimal methodology for a larger UK-
wide study, and secondly to collect information to iden-
tify potential risk factors associated with MPNs. The long 
survival and high prevalence of MPNs, particularly PV 
and ET, has permitted individuals to experience changes 
in clinical classification of their disease over time. Under-
standing of true MPN classification may be unknown to 
patients because of this and other factors. As part of the 
study on epidemiology and quality of life we were able 
to collect clinician derived data regarding patients MPN 
diagnosis, and we aimed to assess patient perception of 
their disease nomenclature and classification.
Results
Overall, 106 MPN patients (37 PV, 55 ET and 14 PMF) par-
ticipated in the study. Patient characteristics are presented 
in Table  1. Patient reported treatments were aspirin (76), 
hydroxycarbamide (13) trial (3) interferon alpha (3) anagre-
lide (1), venesection (3), danazol (1) and erythropoietin (1).
Remarkably, only 76.4 % of patients reported their diag-
nosis as MPN to any of the 3 questions during the tele-
phone interview with 39.6 % of patients recognising MPN 
as a ‘blood condition’, 23.6 % as ‘cancer’, and 13.2 % acknowl-
edged their MPN as an ‘other condition’ see Table 2. Only 
one patient recorded both ‘blood condition’ and ‘cancer’ 
and there was no other overlap between categories.
ET patients were significantly more likely than PV 
patients not to report their condition at all (p =  0.037) 
and significantly more likely than PV and PMF patients 
combined (p = 0.021).
Patients with PV were more likely than those with ET, 
but not PMF, to report their disease as a ‘blood condition’ 
(p = 0.039 and p = 0.943, respectively). A similar propor-
tion of ET and PMF patients reported their condition as a 
‘blood condition’ (p = 0.835).
There were no significant differences in the proportion 
of patients reporting their condition as ‘cancer’ (PV vs. 
ET, p =  0.215; PV vs. PMF, p =  0.321 and ET vs. PMF, 
p = 0.923). Similarly, there were no differences in report-
ing as ‘other condition’ (PV vs. ET, p = 0.706; PV vs. PMF, 
p = 0.488 and ET vs. PMF, p = 0.297).
When adjusted for potential confounding variables of 
MPN subtype, age, gender and educational status, cases 
from Southampton were highly significantly more likely 
than cases from Belfast to report their diagnosis as MPN 
at interview (OR 5.51 95 % CI 1.95–15.53, p = 0.001). Age 
and education level did not affect whether or not patients 
reported their diagnosis during the interview (p = 0.365 
and p = 0.448, respectively).
Reporting of MPN as a ‘cancer’ by patients diagnosed 
before or after the WHO classification change in 2008 
did not significantly differ (18.4 vs. 28.1  %, p  =  0.241). 
There were also no significant differences in reporting 
MPN as a ‘blood condition’ (38.8 vs. 40.4 %, p = 0.869), 
an ‘other condition’ (16.3 vs. 10.5 %, p = 0.379), or not at 
all (26.5 vs. 21.1 %, p = 0.508) before or after 2008.
Discussion
To our knowledge, this is the first time that assessment of 
MPN classification from a patient perspective has been 
ascertained. In a group of patients who had volunteered 
Table 1 Characteristics of MPN patients
Polycythemia 
vera
Essential  
thrombocythemia
Primary 
myelofibrosis
Location
 Southampton 24 (64.9 %) 31 (56.4 %) 11 (78.6 %)
 Belfast 13 (35.1 %) 24 (43.6 %) 3 (21.4 %)
Gender
 Male 13 (35.1 %) 19 (34.6 %) 10 (71.4 %)
 Female 24 (64.9 %) 36 (65.5 %) 4 (28.6 %)
Age (years)
 Mean (SD) 62.1 (13.2) 63.2 (13.4) 66.9 (4.2)
Education
 Pre-University 25 (67.6 %) 37 (67.3 %) 12 (85.7 %)
 University 12 (32.4 %) 16 (29.1 %) 2 (14.3 %)
 Did not report 0 2 (3.6 %) 0
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for the study on the basis of their diagnosis, the variable 
reporting of what they believe their condition to be is 
intriguing. However, no major factors could be identified 
which may shed any light on these variations. There were 
no significant differences in reporting diagnosis by age, 
gender, or level of education.
We did observe some differences in perceptions 
between MPN subtypes. Patients with PV were more 
likely to report their disease as a ‘blood condition’ than 
those with ET. This may be due to many patients with PV 
requiring regular venesections acting as a prompt to the 
nature of the disorder. Likewise, the finding that patients 
with ET were the least likely to report any relevant condi-
tion may be due to their receiving less treatment inter-
vention overall than other MPN subtypes.
A particular issue for MPN patients and clinicians has 
been the WHO definition change from Myeloprolifera-
tive disorders (MPD) to myeloproliferative neoplasms 
(MPN) in 2008 due to the acquired clonal nature of the 
disorders leading to their new definition as a form of 
cancer. This change took time to filter through to clini-
cians and patients who may not be willing to reclassify 
their initial diagnosis. The reclassification provoked a lot 
of controversy in patient forums and this may have influ-
ence in the wider patient arena. Interestingly, our data 
show that there was no significant difference between 
the cohorts diagnosed before or after 2008 in the pro-
portion of patients volunteering their diagnosis as can-
cer despite this change occurring over 7 years ago. This 
may reflect a reluctance to label MPN as cancer on the 
part of hematologists as well as patients and this merits 
further study.
We observed that patients recruited from Southamp-
ton were 5 times more likely to report their diagnosis 
as MPN than patients recruited from Belfast. That this 
effect was independent of educational status is highly 
suggestive that the difference may be in the way the diag-
nosis has been imparted. Clinicians may explain diagno-
ses to patients in different formats for a variety of reasons 
including truth telling custom and varying cultural prac-
tices [18]. There may be differences in patient and clini-
cian reports on diagnostic information conveyed [19, 20] 
with clinicians perhaps avoiding using the word cancer 
due to the distress this can cause.
We did not identify any differences in reporting of 
disease by gender, age or educational level which is per-
haps a little surprising. Certainly in some other studies 
older age and higher levels of education are associated 
with more awareness of a terminal cancer diagnosis [21]. 
Older patients have also been seen to be more likely to 
deny a cancer diagnosis [22]. Recently diagnosed patients 
will have had access to a greater range of patient informa-
tion from both health care professionals, patient support 
groups and the internet yet we have not found here any 
greater awareness in those recently diagnosed.
Moreover patients have different personalities and 
different coping structures. This may impact on how 
they perceive their diagnosis and information given to 
them [23] and of course denial is one particular coping 
structure for some cancer patients [22]. Furthermore, 
some patients may have contrasting priorities in health 
seeking behaviour with some gathering more informa-
tion outside of the clinical setting than others. Finally, 
not acknowledging MPN diagnosis or not classifying 
MPN as a cancer could reflect patient concerns about 
perceived financial and insurance disadvantages of full 
disclosure.
It needs to be recognised that this group of MPN 
patients were being asked to volunteer their diagno-
sis over the telephone. Different replies may have been 
obtained if patients were asked to recognise their diagno-
sis from a menu choice provided by the interviewer. Fur-
thermore, those patients who volunteered a diagnosis of 
MPN were not subsequently questioned specifically as to 
whether they recognised this as a form of cancer in view 
of the sensitivity surrounding this issue.
Further larger scale investigation to address these 
remaining ambiguities in MPN classification from a 
patient viewpoint is warranted.
Methods
The pilot MOSAICC (myeloproliferative neoplasms: 
an in-depth case–control) study was a feasibility study 
which recruited 106 MPN patients and 127 controls. 
Table 2 Patient recall of mpn diagnosis and classification
a As recorded on the medical proforma completed by the patients consultant hematologist
MPN subtypea Patient reporting of MPN in the telephone questionnaire Total
Did not report Blood condition Cancer Other condition
PV 5 (13.5 %) 21 (56.8 %) 6 (16.2 %) 5 (13.5 %) 37
ET 18 (32.7 %) 16 (29.1 %) 15 (27.3 %) 6 (10.9 %) 55
PMF 2 (14.3 %) 5 (35.7 %) 4 (28.6 %) 3 (21.4 %) 14
Total 25 (23.6 %) 42 (39.6 %) 25 (23.6 %) 14 (13.2 %) 106
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MPN patients were recruited from two sites: Belfast City 
Hospital, Belfast, Northern Ireland and University Hospi-
tal Southampton NHS Foundation Trust, Southampton, 
England. Eligible patients were identified by their con-
sultant hematologist (MFMcM, Belfast and ASD, South-
ampton) and classified according to the WHO diagnostic 
criteria [5]. Interviews were conducted by a biomedical 
scientist. Information was ascertained from participants 
through a structured telephone administered question-
naire and information sheets which included demo-
graphic, medical history, residence history, occupation, 
life style and quality of life (QoL) questions. Interviews 
lasted 45 min on average. Information on gender and age 
at the time of interview were obtained. Level of educa-
tion was obtained and patients classified as having pre- 
or post-University education.
In relation to medical history patients were asked 
“Have you been diagnosed with any blood conditions?”, 
“Have you ever been diagnosed with cancer?” and 
“Before a year ago did a doctor ever tell you that you had 
any other medical condition?” in sequence. If the patient 
responded ‘yes’ to any of these questions further details 
were obtained about the condition, date of diagnosis and 
treatment and were transcribed using the patient’s own 
language. Exact details of patient MPN sub-type, year of 
diagnosis and treatment regimens were collected through 
use of a proforma via access to medical records by their 
treating hematologist. Ethical approval was obtained 
from the Office for Research Ethics Committee, North-
ern Ireland (OREC-NI) and the study registered on the 
NIHR portfolio in England and Wales.
Statistical analysis
Crude and adjusted logistic regression analyses were uti-
lised to evaluate the role of gender, age (mean and SD), 
education (pre-/post-University) and location (South-
ampton vs. Belfast), in whether or not a patient reported 
their diagnosis during interview with co-adjustment for 
these variables. Chi square tests were used to investi-
gate the association between MPN subtype and patient 
reported categorisation of MPN (‘blood condition’, ‘can-
cer’, ‘other condition’).
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